ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.

The company's pipeline currently contains five drug candidates, including derazantinib, which has been granted orphan drug designation by the FDA and EMA.

ArQule trades on the NASDAQ exchange under the ticker ARQL.